BRAF and colorectal cancer: Although we do not present data in support of this hypothesis in this study, the frequency in which WNT16 is mutated in BRAF mutant colorectal cancers may provide an impetus for investigating whether WNT16 has a role in determining sensitivity to WNT-ligand inhibitors.